CancerNCT07776587
Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients
A study testing Yoga Therapy (YT) in people with Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Yoga Therapy (YT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2027to 13 Apr 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female cancer patients
- Age 18 or older
- Understand and read English
- Scheduled to undergo their first autologous or allogeneic HSCT (even number of each) at MDA with a minimum of 2-week inpatient hospital stay
- Be willing to follow protocol requirements
- Sign a written informed consent
Who cannot join
- Have extreme mobility issues that preclude participating in the Yoga program
- Have major thought disorders such as schizophrenia or uncontrolled bipolar disorder
- Have hematopoietic cell transplantation HCT comorbidity score of 3 or higher (excluding cancer)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson Cancer Center
Houston, Texas, 77030
Lorenzo Cohen, PHD, 713-745-4260, lcohen@mdanderson.org
Lorenzo Cohen, PHD
About this study
Official title: Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program.
Read the detailed description
Primary Objective:
- Examine the efficacy of YT relative to SC on HSCT-specific QOL. Outcomes will be collected at baseline pre-transplant (pre-YT) and then day 0, 14, 30, 60, and 100 as well as 1-year post-transplant.
Secondary Objectives and Endpoints:
- Examine group differences in other patient-reported outcomes including general QOL and fatigue.
- Explore group differences in psychosocial and functional outcomes and as possible mediators including stress, mental health (depression and anxiety), sleep disturbances, growth, self-efficacy, mindfulness, and objective functional measures as well as moderators of YT including demographic factors (sex, age, etc.), baseline psychosocial factors, and medical variables (e.g., autologous versus allogeneic transplant).
- Explore YT's implementation through qualitative interviews.
- Conditions
- Cancer
- Being tested
- Yoga Therapy (YT)
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Yoga Therapy (YT)Other
Yoga Therapy (YT) is an evidence-based mind-body practice recommended for cancer to relieve nausea, fatigue, pain, sleep disruption, psychosocial distress, musculoskeletal symptoms, and cognitive dysfunction, all common symptoms experienced during HSCT.
| Study group | Role | What they receive |
|---|---|---|
| SC: Enhanced Stand of Care Group | Experimental | In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first Receives: Other: Yoga Therapy (YT) |
| YT: Yoga Group | Experimental | In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first Receives: Other: Yoga Therapy (YT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start1 Feb 2027 (estimated)
- Primary completion13 Apr 2030 (estimated)
- Study completion13 Apr 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Sponsor
- Investigators
- Lorenzo Cohen, PHD, Principal investigator, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07776587
- Sponsor's protocol ID
- 2026-1004
- Other IDs
- NCI-2026-06046
- Status last verified
- Aug 2026
- First submitted
- 17 Aug 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
- ClinicalTrials.gov ID
- NCT07776587
- Acronym / sponsor ID
- 2026-1004
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Study start
- 1 Feb 2027 (estimated)
- Primary completion
- 13 Apr 2030 (estimated)
- Study completion
- 13 Apr 2032 (estimated)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program.
Detailed description
Primary Objective:
- Examine the efficacy of YT relative to SC on HSCT-specific QOL. Outcomes will be collected at baseline pre-transplant (pre-YT) and then day 0, 14, 30, 60, and 100 as well as 1-year post-transplant.
Secondary Objectives and Endpoints:
- Examine group differences in other patient-reported outcomes including general QOL and fatigue.
- Explore group differences in psychosocial and functional outcomes and as possible mediators including stress, mental health (depression and anxiety), sleep disturbances, growth, self-efficacy, mindfulness, and objective functional measures as well as moderators of YT including demographic factors (sex, age, etc.), baseline psychosocial factors, and medical variables (e.g., autologous versus allogeneic transplant).
- Explore YT's implementation through qualitative interviews.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SC: Enhanced Stand of Care Group | Experimental | Other: Yoga Therapy (YT)In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first |
| YT: Yoga Group | Experimental | Other: Yoga Therapy (YT)In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male and female cancer patients
- Age 18 or older
- Understand and read English
- Scheduled to undergo their first autologous or allogeneic HSCT (even number of each) at MDA with a minimum of 2-week inpatient hospital stay
- Be willing to follow protocol requirements
Key exclusion criteria (3 listed)
- Have extreme mobility issues that preclude participating in the Yoga program
- Have major thought disorders such as schizophrenia or uncontrolled bipolar disorder
- Have hematopoietic cell transplantation HCT comorbidity score of 3 or higher (excluding cancer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Yoga Therapy (YT)Yoga Therapy (YT) is an evidence-based mind-body practice recommended for cancer to relieve nausea, fatigue, pain, sleep disruption, psychosocial distress, musculoskeletal symptoms, and cognitive dysfunction, all common symptoms experienced during HSCT. | Other | SC: Enhanced Stand of Care Group, YT: Yoga Group |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lorenzo Cohen, PHD principal investigator
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Yoga Therapy (YT) in people with Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lorenzo Cohen, PHD ((713) 745-4260, lcohen@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.